ArticleJournal of asthma and allergy2018
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
Article in Journal of asthma and allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Pooled it
- Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.The European respiratory journal · 2024Guideline
- Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Treating allergic bronchopulmonary aspergillosis with hormone therapy: natural disease course, regimens, compliance, and outcomes.Frontiers in medicine · 2026Article
- A Multicenter Retrospective Study Evaluating IL-5-Targeted Biologic Therapies for the Treatment of Asthma and Allergic Bronchopulmonary Aspergillosis in Adults With Cystic Fibrosis.CHEST pulmonary · 2025Article
- Review
- Artificial Intelligence Techniques to Predict the Airway Disorders Illness: A Systematic Review.Archives of computational methods in engineering : state of the art reviews · 2023Review
- The immune response to airway mycosis.Current opinion in microbiology · 2021Review
- Allergic Diseases Caused byAntibiotics (Basel, Switzerland) · 2021Review
- Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome.Current allergy and asthma reports · 2021Review
- Immunomodulation in Cystic Fibrosis: Why and How?International journal of molecular sciences · 2020Review
- Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Frontiers in pediatrics · 2020Review
- Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection.Respiratory medicine case reports · 2019Article
- Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review.Therapeutic advances in respiratory diseaseReview
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to
methodsA retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing.
resultsThe database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes.
conclusionNo benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.